We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3 þ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initially engrafted; subsequently, 12% lost the graft, 21% achieved complete donor chimerism and 67% had mixed chimerism (MC). Patients underwent delayed taper of cyclosporine (CsA) if they had MC. Overall survival was 87 ± 7% (s.d.) at 5-years post transplant, and it was not affected by chimerism status. Both WB and CD3 þ chimerism showed significant fluctuations with a peak in autologous cell signal occurring at a median of 7 months for WB and 2 months for CD3 þ cells. Initial post transplant chimerism percentage in either WB or CD3 þ lineage was not related to graft loss. Increasing MC to 430% host cells was seen in 33% of patients, and it was related to increased risk of graft loss, as previously published. However, 63% of children with increasing MC did not lose their graft. Additional studies of post transplant chimerism are required to improve our ability to accurately identify children at risk of graft loss following transplant for non-malignant disorders.
Introduction
Mixed hematopoietic chimerism is defined as the coexistence of donor and recipient hematopoietic cells following allogeneic hematopoietic stem cell transplantation (HSCT).
Post transplant chimerism is affected by the amount of pretransplant chemotherapy, the intensity of the conditioning regimen and the cellular content of the graft.
1,2 Mixed chimerism (MC) is related to increased risk of relapse in patients with acute leukemia, and low levels of donor CD3
þ and natural killer cell chimerism correlate with an increased risk of graft rejection. [3] [4] [5] However, the presence of MC is associated with a decreased incidence of acute graft-versus-host disease (aGVHD). 6 Myeloablative conditioning more commonly eradicates the recipient's hematopoietic cells and results in complete donor hematopoietic chimerism, whereas reduced intensity or non-myeloablative conditioning regimens frequently result in MC. 3, [7] [8] [9] [10] In most non-malignant diseases, such as hemoglobinopathies, immunodeficiencies and marrow failure syndromes, complete donor chimerism (CDC) is not required for the reversal or cure of the underlying disease. However, graft rejection remains a significant problem in transplants for non-malignant diseases. Early post transplant chimerism testing may help to identify patients at increased risk of graft rejection, and some authors have used post transplant chimerism results as a guide for initiating immunotherapy with donor lymphocyte infusions (DLI). 4, 11 However, experience in patients with hemoglobinopathies indicates that chimerism can fluctuate for years following transplant and, once tolerance of donor cells is achieved, rejection does not occur even with a very low percentage of donor WB engraftment. [12] [13] [14] [15] [16] [17] Our institution has been using fludarabine-based conditioning regimens for children with non-malignant disorders since the year 2000. 8 We introduced routine post transplant short-tandem repeats (STR) subset chimerism testing in January 2001. We performed serial testing of chimerism in WB and CD3 þ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing allogeneic transplant for non-malignant disorders.
Patients and methods
The study included 24 children (median age 7.6 years, range (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) ) undergoing first unmodified allogeneic HSCT for a non-malignant disorder at University of California, San Francisco, (UCSF) Children's Hospital, Pediatric Blood and Marrow Transplant Unit (PBMTU) between January 2001 and March 2007. Only patients who received fludarabine-or cyclophosphamide-based conditioning regimen and had chimerism testing done by the STR technique were included. During the study period, a total of 39 children with non-malignant disorders underwent 43 transplants. The reasons for exclusion included: haploidentical T-cell depleted transplant (N ¼ 2), lack of serial chimerism testing or use of XY-in situ hybridization chimerism testing (N ¼ 8) and use of some other conditioning regimen (N ¼ 5). The majority of enrolled patients (N ¼ 19) were treated in one of the two prospective studies that determined chimerism follow-up. The remaining five patients had severe aplastic anemia and matched sibling donors, received standard cyclophosphamide-based conditioning and were not treated on a prospective investigational protocol.
The study was approved by the UCSF Committee on Human Research. Demographics, transplant-specific data and chimerism results were collected from the PBMTU database and the medical records of the patients. We gathered data on disease, conditioning regimen, GVHD prophylaxis, stem cell source and amount, donor and recipient's CMV serology, transplant-related complications, transplant outcome and WB and CD3 þ cell chimerism results.
Conditioning regimens and GVHD prophylaxis
Details of the conditioning regimens and cyclosporine (CsA) taper are summarized in Table 1 . The busulfan, fludarabine and rATG conditioning regimen was replaced with a busulfan, fludarabine and Campath regimen in 2005. 8 GVHD prophylaxis consisted of CsA and methotrexate. CsA was started as a continuous intravenous infusion on day À1 at a dose of 3 mg/kg/day after a loading dose of 1.5 mg/kg. Trough levels were kept between 150 and 250 ng/ml. Methotrexate was given on day þ 1 at a dose of 15 mg/m 2 , and a dose of 10 mg/m 2 on days þ 3, þ 6 and þ 11. In one patient (UPN 493), methylprednisolone was used instead of methotrexate and was given at 1 mg/kg/day on days 0-7 and at 2 mg/kg/day on days 8-21. Subsequently, it was tapered by 0.2 mg/kg/week. CsA taper schedules are summarized in Table 1 .
For transplants involving unrelated donors, HLA matching was determined using high resolution HLA-A, -B, -C and DRB1 typing. Donors were either HLA matched or had a single class I HLA mismatch. For transplants involving related donors, HLA matching was determined using low/intermediate resolution typing for HLA-A, -B and -C and high resolution typing for HLA-DRB1. Bone marrow was the preferred stem cell source; however, peripheral blood stem cells were used if the donor was significantly smaller than the recipient, or if the donor favored peripheral blood stem cell donation. GVHD was graded using published criteria. 18, 19 Chimerism analysis Donor chimerism was determined using a quantitative PCR-based method involving amplification of genes containing STR sequences. ABI 3100 sequencer was used. For each donor-recipient pair, informative alleles were determined for a panel of STR loci (CSFR, VWF, D21S11, D11S1294, D18S51, D16S486, D4S243, AMGY/AMGXA, HUMFIBRA, PENTA D and PENTA E). One or two loci were selected for post transplant testing for each donorrecipient pair. After transplant, donor chimerism was determined for peripheral blood and CD3-selected cells. CD3 þ cells were isolated from a peripheral blood mononuclear cell fraction from a Ficoll gradient using Miltenyi magnetic particles. DNA was isolated from whole blood (WB) or CD3 þ cells using spin columns containing a silicagel membrane (QIAgen, Valencia, CA, USA). The size of amplified fragments was determined using an automated nucleotide sequences (Applied Biosystems, Foster City, CA, USA) and the quantity of each PCR product was determined using peak areas. The percentage of donor alleles was calculated from individual proportions of donor and recipient peak areas. Standard curves constructed using donor and recipient DNA were used to correct for The first chimerism test was done once the absolute neutrophil count reached 500 for 3 consecutive days. If the patient had CDC in all cell subsets at the first chimerism testing, the testing was repeated every 3 months for the first 2 years post transplant and annually thereafter. If the patient had MC, the test was repeated every 2 weeks until a trend of increasing donor chimerism in either WB or CD3 þ lineage was documented. Subsequently, the test was repeated every month for the first year post transplant, every 3 months during the second year post transplant and then annually for the duration of follow-up. Five hundred and forty-six chimerism data points for WB and CD3 þ subset were analyzed. The median number of chimerism tests per patient was 10 (range 3-29).
Definitions of chimerism Complete donor chimerism. As STR chimerism testing has a sensitivity of 1%, donor chimerism percentages X99% on both WB and CD3
þ cell analyses was defined as CDC.
Mixed chimerism. Any donor chimerism percentage below 99% was considered MC.
Increasing mixed chimerism. Increasing MC was defined as significant increase in percentage of host cells (or decrease in percentage of donor cells) in WB between two consecutive assessments that resulted in 430% host cells (or o70% donor cells). This definition follows the one previously published. 4 Hoelle and co-workers defined significant change as 45%, observed on a weekly test. Because our testing was done every other week, we considered a change of X10% to be significant (that is, a decrease in donor cells from 78 to 68% would represent increasing mixed chimerism). CD3 þ chimerism was not taken into consideration in this definition.
Stable mixed chimerism. Patients who had X70% of donor cells on all WB chimerism tests were defined as having stable MC.
Graft loss. Loss of graft function (such as pancytopenia) in the setting of decreasing donor WB and CD3 þ chimerism was defined as graft loss.
We used o50% of donor CD3 þ cell chimerism when evaluating the risk of graft loss, as some studies indicate that o50% of donor CD3 þ cell chimerism in the early post transplant period (day þ 14-28) correlates with the increased risk of graft loss/rejection.
1,2,5
Graft function. The graft was considered functional if it resulted in correction of the underlying disease. Graft function was evaluated using disease-specific measures, such as transfusion independence in marrow failure syndromes and hemoglobinopathies; immune reconstitution and lack of infection in immunodeficiencies; enzyme level, brain imaging and neurologic exam in patients with metabolic disorders and absence of symptoms and discontinuation of pre-transplant-specific therapies in patients with autoimmune disorders.
All patients with MC had delayed taper of CsA as described in Table 1 . No other therapeutic decisions were based on the results of chimerism testing.
Statistical analysis
Survival was calculated using Kaplan-Meier analysis from the time of transplant until the last contact for living patients or date of death for deceased patients. Log rank testing was used to compare survival rates. We used a twotailed t-test for comparison of continuous variables and Fisher's exact test with two-sided P-values for comparison of categorical variables. Linear regression lines were used to illustrate the trend of chimerism within a subgroup ( Figure 1 ). All data analysis was performed using the SPSS statistical program (SPSS Inc., Chicago, IL, USA). Table 2 shows the details of patients' characteristics. There were 18 male and 6 female patients. Median age at transplant was 7.6 years (range 1-17). Only two patients received prior therapy with immunosuppressive agents (UPN 498 and 1046). All other patients received only supportive therapy prior to transplant. Fourteen patients underwent matched related transplants, and 10 received unrelated transplants (eight fully matched and two oneantigen or allele mismatched transplants). All patients initially engrafted; two rejected the graft early and one developed late graft loss (Table 2) .
Results

Patients' characteristics and transplant outcomes
Three patients died, all with the diagnosis of adrenoleukodystrophy. The Kaplan-Meier test indicates 87±7% (s.d.) an overall survival rate at 5-years post transplant. Increasing mixed chimerism and the risk of graft loss E Ozyurek et al Increasing mixed chimerism and the risk of graft loss
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Living patients were followed for a median of 31 months (range 9-76). Twenty-three percent (5/22 patients who did not reject the graft early) developed aGVHD. The same five patients developed chronic GVHD and two died. At the last follow-up, the three surviving patients were off immunosuppression and lacked evidence of chronic GVHD.
Chimerism results
Chimerism is summarized in Table 3 , which shows the results of the first chimerism test obtained at the time of neutrophil engraftment (30 ± 15 days post transplant), the lowest percent of donor WB and CD3 þ chimerism and the most recent chimerism result. The median time to last chimerism follow-up was 26 months (range 8-58 months) for living patients without graft rejection.
Whole-blood chimerism. On the first chimerism test, 10 patients had X99% donor cells and all patients had X70% of donor cells. However, in 19/24 (79%) patients, the proportion of donor cells decreased from the initial level, at a median of 7 months after transplant (range 2-34 months). In eight patients, the decrease in donor cells was significant, and it resulted in a proportion of host cells that exceeded 30%; thus 8/24 (33%) patients were categorized as having 430% host cells (increasing MC). At the last follow-up, 3/ 24 patients (12%) had rejected their graft, 5/24 (21%) were complete donor chimera and 16/24 (67%) were mixed chimera.
CD3
þ chimerism. On the first chimerism test, 9/18 (50%) patients for whom the early CD3 þ chimerism result was available had X50% donor cells in the CD3 þ cell subset. In 10/18 (56%) patients, the percentage of donor CD3 Graft loss. Two patients developed early graft rejection (UPN 517 and 1104) and one (UPN 434) developed late graft loss. Both patients who developed early graft rejection had initial WB engraftment of X70%. One had CD3 þ engraftment of 63% and the other had 1% donor CD3 þ cells on the first engraftment test. Graft rejection presented with symptoms of high fever, rash, pancytopenia and a decrease in donor chimerism in both patients. They underwent a second transplant at 2 months following the first one. One patient survived, and one died from toxicities þ chimerism showed 23% donor cells. Because of graft dysfunction, he underwent a second transplant from the same donor following myeloablative conditioning and is alive today.
Neither o70% of donor chimerism in WB nor o50% of donor CD3 cell chimerism obtained on the initial chimerism test post HSCT correlated with the risk of graft loss (Fisher's exact P-value 0.5 and 0.2, respectively). However, a subsequent decrease in WB chimerism (development of increasing MC) was related to increased risk of graft loss (P ¼ 0.03). A decrease in the CD3
þ donor cell population to below 50% was not related to graft failure (P ¼ 0.3). Graft loss developed in 3 out of 8 (37.5%) patients with increasing MC and in none out of 11 patients with stable MC. The overall survival of patients with stable MC and CDC was 86.5 ± 9%(s.d.) and is not different from the survival of patients with increasing MC, including those who developed graft loss which was 87.5±9%(s.d.), respectively.
WB and CD3 þ chimerism trends. Figure 1 illustrates the trend (represented by the linear regression line) of WB and CD3 þ chimerism in patients with stable MC (N ¼ 11). Patients with stable MC frequently started with a low percentage of donor CD3 þ cells. However, over time, donor CD3 þ chimerism as well as WB chimerism increased. At the last follow-up, the majority of patients (10/11) had a higher percentage of donor cells in WB than in the CD3 þ lineage (Table 3 ). Figure 2 shows WB and CD3 þ chimerism data on eight patients with increasing MC. The x axis reference line marks the chimerism test at which the patient was classified as having increasing MC. Increasing MC developed between 1.5 and 6 months post transplant. All three patients who subsequently rejected their grafts developed increasing MC before 2 months post transplant. At the time of diagnosis of increasing MC, donor CD3 þ chimerism was 450% and with an increasing trend in 2/8 patients (UPN 1126 and 1186) , and in the other 6 patients CD3 þ chimerism was o50% or did not have an established trend.
Post transplant graft function and mixed chimerism All except three living patients who did not reject their grafts had full correction of their underlying disease at last follow-up. At last follow-up, one patient (UPN 501) with chronic granulomatous disease continues to have two populations of granulocytes, one with abnormal and one with normal neutrophil oxidative burst activity. During the early post transplant course he had frequent infections, none of which were typical for chronic granulomatous disease and received unmobilized peripheral blood DLI at 
Discussion
Although CDC is a desirable outcome of allogeneic transplant for malignant disorders, stable MC is sufficient for correction of most underlying non-malignancies. Due to the decreased incidence of GVHD, stable MC is often the preferred outcome after an allogeneic transplantation for a non-malignant disorder. However, achieving the precise level of MC at which the risk of rejection is negligible is an elusive goal.
Previous studies have found that patients with a significant increase in the proportion of host cells (increasing MC) on their post transplant WB chimerism tests have an increased risk of rejection. 4, 11, 15 Andreani et al. 13 showed an 84% rejection rate in patients with thalassemia who had 425% autologous cells in WB at 2 months post transplant, and Baron et al.
1,2 and Matthes-Martin et al. 5 showed that low donor CD3 þ and natural killer cell chimerism at days 14 and 28 post transplant correlated with graft rejection. Long-term follow-up of patients with thalassemia showed that once tolerance to donor cells has been established, graft rejection does not occur even at low levels (o10%) of donor WB engraftment. 13, 17, 21 Thus, the risk of rejection after allogeneic transplant may be limited to a period before the development of tolerance, suggesting that chimerism testing may not be predictive of rejection, once tolerance to donor cells has been established. However, the understanding of tolerance development following transplantation for non-malignant disorders is incomplete.
Unlike for hematologic malignancies, where achieving 100% donor engraftment is always desired, in nonmalignant disorders the amount of donor cells required for sustained engraftment and correction of underlying disease may be host and disease specific. For example, while most children with primary immunodeficiency disorders such as SCID develop normal immune function with a low level of donor chimerism, some children with Wiskott-Aldrich syndrome may require CDC to control symptoms of autoimmunity. 22, 23 The incidence of increasing MC was 33% in our study which is within the range of published results. Hoelle et al. 4 reported an incidence of 13% in a cohort of children with severe aplastic anemia receiving CD34 þ enriched transplants, and Willasch et al. 11 reported a 34% incidence of increasing MC in children with non-malignancies conditioned with busulfan, cyclophosphamide and antithymocyte globulin, 70% of whom received T-cell depleted transplants. Two apparently contradictory approaches have been used to decrease the risk of rejection. The first consists of prolonged immunosuppression to achieve a state of tolerance between donor and recipient cells, and the second consists of prompt discontinuation of immunosuppression followed by additional donor cells with a goal of enhancing donor engraftment. Willasch et al. 11 used the second approach in 19 children who developed increasing MC following T-cell depleted transplants for non-malignant disorders. With this approach, the graft loss rate in Increasing mixed chimerism and the risk of graft loss E Ozyurek et al children with increasing MC was 16%, as opposed to 37.5% in our patients who underwent delayed CsA withdrawal as the only intervention. 11 The results of Willasch et al. 11 suggest that frequent chimerism testing in the post transplant period has a possibility of detecting impending graft rejection early enough to allow intervention.
Although preemptive use of DLI appears to be effective in preventing graft-rejection, in our study, use of DLI would not be feasible in two patients who developed early graft rejection as their symptoms of graft rejection were difficult to distinguish from aGVHD. However, our patient with late graft failure might have been a good candidate for DLI.
The definition of 'increasing MC' identified all patients at risk of rejection, as no patient with X70% of donor cells in WB chimerism rejected the graft. However, the majority of patients with 'increasing MC' did not reject the graft in our study. It is possible that prolonged immunosuppression modified the risk of rejection in our patients, or that the previous studies used DLI in a number of patients who would not have rejected the graft if left untreated.
We explored whether chimerism in the CD3 þ lineage could provide additional information about the risk of graft loss. Unfortunately, we did not determine natural killer cell chimerism, which has been proposed to be a better predictor of late graft rejection than WB or CD3 þ cell chimerism.
1,5 CD3 þ chimerism showed significant variability, and frequent declines to low levels even in patients with stable MC. Differences among patients in cellular graft content, in vivo CD3 þ cell depletion and occurrence of host clonal T-cell expansion due to infections, might have contributed to fluctuations and declines that we observed in CD3 þ chimerism. The trough in donor CD3 þ chimerism was reached by 4 months post transplant in majority of patients after which the CD3 þ chimerism established an upward trend. This upward trend may indicate that the tolerance of donor cells has been established and that rejection is not likely. Thus, intervention may not be necessary regardless of the WB chimerism level once donor CD3 þ chimerism is showing a steady increase. However, our observations require confirmation on a larger number of patients.
The decision about using an intervention to prevent graft rejection or enhance engraftment in children undergoing a transplant for non-malignant disorders should be based on understanding an individual patient's risk of rejection. That risk will depend on a number of factors including the underlying disease, pre-transplant therapies, conditioning regimen, the stem cell source and cellular content and the level of donor chimerism. 1 To improve our ability to predict the risk of graft loss more precisely, further studies of these factors are required.
